• HOXC8, Caspase-1, and Lung Tumorigenesis

  2026-08-09

  The reference study identifies HOXC8 as a transcriptional suppressor of CASP1 in non-small cell lung carcinoma, linking its loss to caspase-1-dependent pyroptosis rather than conventional apoptosis. Its mechanistic model connects HOXC8 with HDAC1/2 recruitment at the CASP1 promoter and shows that cholesterol-conjugated HOXC8 siRNA can restrain tumorigenesis, providing a framework for studying transcriptionally controlled inflammatory cell death.

• Protease Inhibitor Cocktail for Plant Extracts

  2026-08-08

  Learn how the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) supports plant cell protein stability and more reliable downstream assays. This guide connects inhibitor selection with modern insights into protein modification, degradation, and assay interpretation.

• Olaparib Assay Design for G4–BLM Biology

  2026-08-07

  Olaparib and AZD2281 can serve as mechanistic probes linking PARP-dependent DNA repair to BLM promoter G-quadruplex biology. This guide translates recent G4–STAT1 findings into practical assay design for cancer research, combination studies, and radiosensitization models.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-08-07

  A recent study demonstrates that naturally occurring angiotensin peptides, including truncated forms like Angiotensin 1/2 (5-7), significantly enhance SARS-CoV-2 spike protein binding to the AXL receptor. This finding bridges cardiovascular peptide biology and viral pathogenesis, revealing new research angles for both hypertension and COVID-19 mechanisms.

• Polybrene (Hexadimethrine Bromide): Precision Viral Transduc

  2026-08-06

  Polybrene (Hexadimethrine Bromide) 10 mg/mL elevates lentivirus and retrovirus transduction efficiency, even in challenging cell lines, by neutralizing electrostatic barriers. Its versatility as a lipid-mediated DNA transfection enhancer and anti-heparin reagent makes it essential for cutting-edge gene delivery and proteomics workflows.

• FAISL lncRNA Blocks FAK Proteolysis in TNBC Progression

  2026-08-06

  The reference study uncovers how the long noncoding RNA FAISL directly inhibits Calpain 2-mediated proteolysis of focal adhesion kinase (FAK), stabilizing FAK protein and driving progression and metastasis of triple negative breast cancer (TNBC). These findings delineate a novel regulatory axis in TNBC and suggest FAISL as a promising therapeutic target.

• Bsa I (RNase-free): Technical Use in DNA Cleavage Workflows

  2026-08-05

  Bsa I (RNase-free) enables precise DNA cleavage in molecular biology research, especially when RNA integrity is essential, such as in gene cloning or recombinant DNA workflows. It is not suitable for diagnostic or clinical applications. RNase-free formulation is critical for protocols sensitive to RNA degradation.

• PP 3 as a Precision Control in Src Kinase Pathway Research

  2026-08-05

  Explore how 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP 3) empowers research use only chemical workflows for dissecting Src kinase signaling pathway specificity. This in-depth review uniquely connects biochemical rigor to recent vascular biology breakthroughs.

• PARP7 Inhibition Stabilizes STAT1/2 and Relieves EAE in Mice

  2026-08-04

  Xu et al. uncover that PARP7 mediates autophagic degradation of STAT1 and STAT2, suppressing type I interferon signaling. Inhibiting PARP7 restores STAT1/2, enhances interferon responses, and ameliorates experimental autoimmune encephalomyelitis in mice, suggesting a novel therapeutic axis for multiple sclerosis research.

• Refining In Vitro Cancer Drug Response: Dual Metrics Approac

  2026-08-04

  Schwartz’s dissertation introduces a dual-metric framework to distinguish between proliferative arrest and cell death in in vitro cancer drug screening. This approach clarifies the multidimensional effects of anti-cancer compounds, informing more precise assay design and interpretation.

• FAISL lncRNA Blocks FAK Proteolysis in TNBC Progression

  2026-08-03

  The reference study reveals that the long noncoding RNA FAISL inhibits Calpain 2-mediated proteolysis of focal adhesion kinase (FAK), stabilizing FAK protein and driving the progression and metastasis of triple negative breast cancer (TNBC). These findings clarify a novel regulatory axis in TNBC, highlighting FAISL as a potential therapeutic target and underscoring the value of precise mechanistic models for FAK signaling.

• EdU Flow Cytometry Assay Kits (Cy3): Precision in Cell Cycle

  2026-08-03

  Unlock unmatched sensitivity and workflow flexibility with EdU Flow Cytometry Assay Kits (Cy3) for S-phase detection. This article details protocol enhancements, troubleshooting, and cross-study applications—including integration with anoikis-based drug sensitivity stratification in breast cancer—empowering researchers in genotoxicity, pharmacodynamics, and beyond.

• Polybrene: Mechanisms and Strategies for Translational Succe

  2026-08-02

  This article delivers an advanced, evidence-driven perspective on Polybrene (Hexadimethrine Bromide) 10 mg/mL, exploring its mechanistic basis as a viral attachment facilitator and its strategic role in modern translational workflows. Bridging protocol rigor with scientific foresight, we provide actionable guidance for researchers navigating gene transduction, transfection, and emerging applications in protein degradation.

• FLOT1–FOSL2–EphA2 Axis Regulates Microglial Polarization in

  2026-08-01

  This study uncovers how the FLOT1–FOSL2 interaction promotes EphA2 transcription, activating the p38/MAPK pathway and driving pro-inflammatory microglial polarization in Alzheimer's disease. Disrupting this axis reduces neuroinflammation and improves cognitive outcomes, highlighting a mechanistic target for modulating neurodegeneration.

• Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe): Lab Protoc

  2026-07-31

  Angiotensin II is an octapeptide reagent for modeling hypertension, vascular smooth muscle cell hypertrophy, and cardiovascular remodeling in vitro and in vivo. It is not intended for diagnostic or therapeutic use. This article outlines practical protocols, QC steps, and troubleshooting strategies specific to research workflows using APExBIO's Angiotensin II.

7999 records 4/534 page Previous Next 12345 下5页 Last page